Polyrizon Enrolls First Patient In U.S. NASARIX Allergy Blocker Trial, Entering Clinical Stage
First patient marks Polyrizon’s transition into a clinical-stage company.The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker in patients with
Polyrizon started testing a new allergy medicine on real patients. This is a big step forward that shows the company is making progress.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.